Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brentuximab Vedotin,Cyclophosphamide,Dacarbazine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves ADCETRIS® (brentuximab vedotin) in Combination with ECADD
Details : Adcetris (brentuximab vedotin) is a CD30 inhibitor, is now approved in combination with lenalidomide and rituximab for the treatment of Stage IIb/III/IV hodgkin lymphoma.
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 03, 2025
Lead Product(s) : Brentuximab Vedotin,Cyclophosphamide,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Toripalimab,Dacarbazine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Junshi Biosciences gets sNDA Approval for Toripalimab in First-Line Melanoma
Details : Tuoyi (toripalimab) is an approved anti-PD-1 monoclonal antibody, which is being evaluated for the first-line treatment of adults with melanoma.
Product Name : Tuoyi
Product Type : Antibody
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : Toripalimab,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Toripalimab,Dacarbazine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Junshi Announces sNDA Acceptance for Toripalimab as First-Line Melanoma Treatment
Details : Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody, which is being evaluated in combination with etoposide & cisplatin for the first-line treatment of unresectable or metastatic melanoma.
Product Name : Tuoyi
Product Type : Antibody
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : Toripalimab,Dacarbazine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable